Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Akero Therapeutics (NASDAQ:AKRO) Chief Technology Officer Scott A. Gangloff sold 848 shares of common stock on June 18, 2025, at prices ranging from $54.73 to $54.84, for a total value of $46,504. The sale comes as the stock trades near its 52-week high of $58.40, having delivered an impressive 133% return over the past year. According to InvestingPro, analysts maintain a Strong Buy consensus on the stock.
The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission. Following the sale, Gangloff directly owns 23,452 shares of Akero Therapeutics.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, according to a footnote in the filing. These sales were automatic under the company’s "sell-to-cover" policy and not at the discretion of Gangloff.
In other recent news, Akero Therapeutics has been in the spotlight due to several significant developments. The company reported promising results from its Phase 2b SYMMETRY trial, published in the New England Journal of Medicine, which showed that their drug efruxifermin (EFX) may improve liver fibrosis in patients with compensated cirrhosis. At week 96, 29% of patients in the EFX 50mg group and 21% in the 28mg group showed fibrosis improvement without worsening of MASH, compared to 11% in the placebo group. Financially, Akero ended the first quarter of 2025 with $1.1 billion in cash, which is expected to support its operations into 2028.
Analysts have been adjusting their outlooks on Akero. Jefferies maintained a Buy rating with a $75 target, highlighting the strong data from Akero’s FGF21 therapy. Citi also kept a Buy rating but adjusted its price target from $80 to $78, reflecting updates from the Phase 2b SYMMETRY trial. Meanwhile, Morgan Stanley (NYSE:MS) lowered its price target from $90 to $84, maintaining an Overweight rating while noting a more cautious timeline for the U.S. launch of EFX treatments for F4 patients.
Clear Street initiated coverage on Akero with a Buy rating and a $49 price target, praising EFX’s potential in treating NASH. The analysts emphasized EFX’s significant efficacy in cirrhosis trials, which could position it competitively in the market. These recent developments underscore Akero’s ongoing clinical progress and the varied analyst perspectives on its future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.